ArticleInternational journal of nephrology2025
Desidustat for the Treatment of Anaemia in Adult End-Stage Kidney Disease Patients on Maintenance Haemodialysis: A Prospective Observational Study.
Article in International journal of nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Anaemia is a prevalent complication in patients with end-stage kidney disease (ESKD), significantly impacting morbidity and mortality. Desidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, offers an alternative to erythropoiesis-stimulating agents for managing anaemia. This study aims to assess the response of haemoglobin and safety and efficacy of desidustat in ESKD patients. Methods: This prospective observational study evaluated the efficacy and safety of desidustat in 50 ESKD patients on maintenance haemodialysis. Patients received 100 mg oral desidustat thrice weekly for 6 months, with regular monitoring of haemoglobin, iron profiles, lipid profiles, and adverse effects. Results: This study demonstrated a 76% response rate to desidustat, with a mean haemoglobin rise of 0.82 g/dL (9.56% increase) over 6 months. Notably, higher baseline serum iron and ferritin levels predicted greater responses. Additionally, desidustat reduced serum ferritin, TSAT, LDL, and total cholesterol levels without impacting blood pressure. Conclusion: Desidustat demonstrated efficacy and safety in ESKD patients on haemodialysis, offering effective haemoglobin management and a favourable safety profile. These findings support desidustat as a viable treatment option for patients with anaemia, providing a valuable alternative to existing therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.